The inhibitory effects of (E)-5-(2-bromovinyl)-2Ј-deoxyuridine (BVDU) and its arabinosyl derivative (E)-
G ene-mediated prodrug activation is a promising therapeutic approach for the treatment of cancer. It relies on the transfer into tumoral cells of a "suicide" gene that encodes an enzyme which, unlike the cellular enzymes, is able to convert a nontoxic prodrug into a toxic metabolite.
The most widely investigated suicide system combines the Herpes simplex virus thymidine kinase-encoding gene (HSVtk) and the antiherpetic drug ganciclovir (GCV).
This guanosine analog is monophosphorylated by the viral kinase and is then converted by cellular enzymes into its triphosphate form, which causes DNA chain termination and cell death. 1 Since it was first described, [2] [3] [4] the HSVtk/GCV system, whose most interesting feature resides in its bystander effect, has been used largely and with success in in vitro assays and on animal models. Its safety and efficacy are being tested in clinical trials against many different types of cancer. 5, 6 However successful this approach may be, the efficacy of the process must be improved and in that context, we have investigated other suicide gene/prodrug systems. We have shown recently that the TK-encoding gene of another herpesvirus, Varicella zoster (VZV), combined with the pyrimidine nucleoside (E)-5-(2-bromovinyl)-2Ј-deoxyuridine (BVDU) is a potent suicide gene/prodrug system both in vitro and in vivo against breast cancer cells. 7 We chose BVDU because it is the best substrate for VZVTK, an enzyme that, in contrast to HSVTK, has a very low affinity for GCV. 8 In in vitro assays, BVDU is one of the most potent inhibitors of VZV replication; 9 it is a 40-fold better substrate of HSV-1 TK than GCV, 10, 11 and it is markedly more cytotoxic than GCV to murine mammary carcinoma (FM3A) cells transfected with HSVtk. 2, 3 In animal models, BVDU is very effective against various herpetic infections in mice, 12 rabbits, 13 and monkeys; 14 it is devoid of toxicity and readily absorbed upon oral administration. 15 In humans, BVDU used as a systemic oral treatment against disseminated VZV infection has no toxic side effects, 16, 17 in contrast to GCV, which must be administered intravenously (i.v.) and has a pronounced hematopoietic toxicity. 18, 19 Avoiding this toxicity may represent an additional advantage for the immune response associated with the bystander effect.
Several BVDU derivatives exist that are similar to the parental drug in their antiviral and pharmacological properties. Among them, (E)-5-(2-bromovinyl)-1-␤-Darabinofuranosyluracil (BVaraU or sorivudine) has emerged as a very potent agent against VZV and HSV-1 replication in vitro, 20 with an enhanced bioavailability. 21 As prodrugs, BVaraU and BVDU have comparable in vitro inhibitory activity on the growth of human osteosarcoma cells transfected with VZVtk. 22 On the basis of these data, we have conducted further studies to investigate the cytotoxic properties of BVDU and BVaraU against viral tk ϩ tumor cells in comparison with the HSVtk/GCV system. The effects of BVDU and BVaraU were measured in vitro and in vivo on the growth of tumor cells expressing either VZVtk or HSVtk after retroviral transduction. Two different cell types, the MDA-MB-435 human breast carcinoma and the 9L rat gliosarcoma cell lines, were used. Our results demonstrated that even though the VZVtk/BVDU, VZVtk/ BVaraU, and HSVtk/BVDU combinations have the same high cytotoxic potential on the tumor cells in vitro, the classical HSVtk/GCV system is more inhibitory in vivo on tumor growth. To shed light on this discrepancy (and possibly to improve the therapy), we have examined the in vivo degradation of BVDU and have found that this process alone cannot explain the observed difference in the antitumoral activity of the drugs.
MATERIALS AND METHODS

Cell lines and cultures
GPϩenvAM12
23 and PA317 24 amphotropic packaging cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (FBS) (Life Technologies, Paisley, UK) and 110 mg/L sodium pyruvate.
The breast cancer cell line MDA-MB-435 was grown in RPMI 1640 (Life Technologies) supplemented with 10% FBS and 10 g/mL insulin. The 9L gliosarcoma cell line was maintained in RPMI 1640 (Life Technologies) supplemented with 10% FBS and 1% nonessential amino acids. All media contained penicillin (10 2 U/mL) and streptomycin (10 2 g/ mL). Cell cultures were maintained at 37°C in 5% CO 2 .
Retroviral vectors and gene transfer
LNPOtk 7 and pTCM1-LTKSN 25 retroviral vectors were used to transfer VZVtk and HSVtk, respectively (Fig 1) . The LNPOtk vector (10 6 colony-forming units/mL) was produced by GPϩenvAM12-transfected cells; the pTCM1-LTKSN vector (3 ϫ 10 5 colony-forming units/mL) was produced by PA317-transfected cells. The retroviral infection of the two tumor cell lines, performed as described previously, 7 generated stable populations of modified cells. The selection of transduced cells was made in the presence of 425 g/mL and 500 g/mL geneticin for MDA-MB-435 cells and 9L cells, respectively.
Quantification of TK activity
TK activity was measured by a deoxythymidine (dThd) kinase assay in the two tumor cell lines that were infected (equals tk) or left uninfected (equals control) by the retroviral vectors carrying either VZVtk or HSVtk. Extracts prepared from Ͼ10 7 cells as described previously 26 were stored in aliquots at Ϫ70°C and assayed for dThd kinase activity as reported previously. 27 The results, expressed in picomoles of [methyl- 
Cytotoxicity assay
MDA-MB-435 and 9L cells that were infected (equals tk) or left uninfected (equals control) by the vectors carrying either VZVtk or HSVtk were tested for their sensitivity to BVDU (Berlin Chemie, Berlin, Germany), BVaraU (Bristol-Myers Squibb, Brussels, Belgium), and GCV (Syntex, Palo Alto, Calif). The cells (2 ϫ 10 4 per well in six-well plates) were cultured for 24 hours and then grown in the drug-containing medium for 10 days. Each drug was tested in triplicate at 6 -10 concentrations ranging from 0.005 to 600 M. The medium was changed every 2 days, and the living cells were counted by the trypan blue exclusion method. The percentage of survival was expressed as a function of the number of cells counted in cultures grown in the absence of the drug. Cytotoxic doses were expressed as IC 50 values (50% inhibitory concentrations required to reduce the survival by 50%), and selectivity indexes were calculated as the IC 50 ratios of noninfected to infected cells. Data were mean values Ϯ SD of two independent experiments.
Tumor growth in nude mice
Transduced MDA-MB-435 breast cancer cells were trypsinized, counted, centrifuged, and resuspended in serumfree medium. They were injected ( 10 6 ) subcutaneously (s.c.) into 5-week-old athymic female mice (nu/nu Swiss mice from Iffa Credo, Brussels, Belgium). Prodrug treatment was for 16 consecutive days, starting at 6 days after cell implantation. The mice were injected intraperitoneally (i.p.) once a day with phosphate-buffered saline (PBS) (n ϭ 6) and with 80 mg/kg/ day of GCV (n ϭ 8), BVDU (n ϭ 6), and BVaraU (n ϭ 6). The tumor size was measured with calipers and expressed in millimeters as the mean value between tumor length and width.
Prodrug sensitivity of residual mammary tumors of treated mice
The drug sensitivity of the residual tumors was checked by re-establishment of the tumors in culture. VZVtk ϩ residual tumors (three per group) of PBS-, BVDU-, and BVaraUtreated mice were collected on day 47 after cell implantation, rinsed twice with PBS, mechanically dislocated in culture medium, and maintained in culture. Three HSVtk ϩ residual tumors collected from PBS-and BVDU-treated mice on day 56 and from GCV-treated mice on days 122-170 were also re-established in culture. The sensitivity of these residual tumoral cells to 10 M of GCV, BVDU, and BVaraU was tested as described above (see "Cytotoxic assay"). Geneticin resistance was determined on dishes (10-cm diameter) by plating 10 6 tumor cells in culture medium containing 425 g/mL geneticin and counting the living cells 1 week later by the trypan blue exclusion method. Percentage of survival was expressed as a function of the cell number counted in parallel cultures without geneticin.
Tumor growth in rats
9L gliosarcoma cells (10 6 ) transduced in vitro with the retroviral vector LNPOtk were implanted s.c. into 16-week-old male Fischer 344 rats (Iffa Credo). After 10 days, the rats were treated i.p. with PBS (n ϭ 3), with 30 mg/kg/day BVDU (n ϭ 10), and with 100 mg/kg/day BVDU (n ϭ 7) for 14 days. The tumor size was measured with calipers and expressed in millimeters as the mean value between tumor length and width.
Clearance of BVDU in the bloodstream of mice and rats
To examine the clearance of BVDU in nude mice and Fischer 344 rats, single doses of 100 mg/kg BVDU were administered i.v. Blood samples were taken at 0, 2, 15, 60, 120, and 360 minutes after drug administration, and the amounts of both BVDU and its degradation product, (E)-5-(2-bromovinyl)uracil (BVU), were determined in animal sera by high performance liquid chromatography analysis as described previously. 28 Data were mean values of triplicate experiments.
RESULTS
Expression of viral tks in tumor cells
Populations of MDA-MB-435 and 9L cells, each carrying VZVtk or HSVtk, were established by infection with the LNPOtk vector 7 and the pTCM1-LTKSN vector, 25 respectively. As shown in Figure 1 , the tk transcription is driven by the viral long terminal repeat in both constructs, but its translation from the internal ribosome entry site (IRES) element is cap-independent in the VZVtk vector, whereas this translation is cap-dependent in the HSVtk vector. To evaluate the influence of this difference, the TK activity was measured in the four tk ϩ cell populations (Table 1 ) using as controls the basal cytosolic and mitochondrial TK activity of the noninfected MDA-MB-435 and 9L cells, respectively. In each infected cell line, the TK activity produced from the two proviruses was similar, indicating that the IRES-driven translation was as efficient as the cap-dependent process. However, the mammary tumor cells displayed higher TK activity than the glioma cells, indicating cell type-specific variations. One may note that the viral dThd phosphorylating activities measured were Ͼ10-fold larger than those reported in other tumor cell populations transfected with VZVtk or HSVtk.
22,27
In vitro cytotoxic activity of the nucleoside analogs The cytotoxicity of BVDU and BVaraU was investigated in vitro on the various tk ϩ cell populations and compared with that of GCV. The results presented in Table 2 , first showed that the compounds tested at concentrations up to 100 M lacked growth-inhibitory activity on the control tumor cells, except that GCV had a 60 M IC 50 7 BVDU also appeared to be a very potent prodrug against HSVtk ϩ cells, because it displayed the same high selectivity indexes on the two tk-expressing cells. As also shown in Table 2 , GCV was not more cytotoxic than BVDU on HSVtkexpressing cells; however, as already reported, 7, 22 GCV was totally devoid of activity on VZVtk ϩ cells. BVaraU and BVDU exhibited the same strong activity on the proliferation of the two VZVtk-expressing tumor cell lines. In contrast, BVaraU at concentrations as high as 400 M was devoid of activity against HSVtk ϩ cells. From these data, it follows that of the six suicide gene/prodrug combinations tested, four killed tumor cells extremely efficiently in vitro.
In vivo activity of the nucleoside analogs on the tk ϩ breast cancer cell tumors The four suicide gene/prodrug combinations (i.e., VZVtk/BVDU, VZVtk/BVaraU, HSVtk/BVDU, and HSVtk/GCV) were compared with respect to their in vivo efficacy. To investigate the antitumoral effect of BVDU on HSVtk ϩ cells, MDA-MB-435 HSVtk ϩ cells (10 6 ) were implanted s.c. in nude mice and i.p. BVDU treatment (80 mg/kg/day) starting at the tumor onset was applied for 16 days. As shown in Figure 2A , BVDU treatment significantly reduced the mean size of the MDA-MB-435 HSVtk ϩ tumors during the treatment period and ϳ10 days afterward. However, mice similarly inoculated with 10 6 HSVtk ϩ tumor cells and then treated with GCV instead of BVDU at the same daily dose experienced a stronger decreased tumor growth (Fig 2, A and B) . Moreover, GCV treatment resulted in complete eradication of the tumors in 50% of the mice (observed for a 6-month period). In contrast, tumor-free animals were not observed in the control or BVDUtreated groups. Consequently, it follows that as a result of treatment with GCV or BVDU, the HSVtk ϩ tumor development was dramatically different, even though the two drugs had similarly high in vitro cytotoxic activity on HSVtk ϩ cells. VZVtk-carrying breast cancer cells (10 6 ) were then inoculated s.c. in mice, and the mice were treated with 80 mg/kg/day BVDU or BVaraU as described above. The effect of BVDU treatment was similar to that observed with the HSVtk ϩ breast cancer cell-derived tumors (Fig 2B, left and right) . In both cases, the tumor size was reduced by 50% at 30 days after cell implantation. However, the tumor sizes for the mice treated with BVaraU instead of BVDU were not reduced to the same extent (Fig 2B, left) .
To test whether the incomplete regression of VZVtk ϩ or HSVtk ϩ mammary tumors was due to a loss of sensitivity to the drug, three residual tumors from each of the mice groups were harvested and re-established in culture. Within 10 days, the three drugs (GCV, BVDU, and BVaraU) at 10 M each killed almost all tumoral cells (96.9 Ϯ 1.3%) derived from PBS-treated animals. However, 19.7 Ϯ 14%, 45.5 Ϯ 16%, and 12.7 Ϯ 1.7% tumor cells of GCV-, BVDU-, and BVaraU-treated mice, respectively, were drug-resistant, and 96 Ϯ 7.5% of all replated cells were still geneticin-resistant, demonstrating that the VZVtk ϩ or HSVtk ϩ tumors that had developed in vivo after drug treatment were formed by a majority of drug-sensitive cells.
In vivo activity of the VZVtk/BVDU system on 9L cell tumors Of the four suicide gene/prodrug combinations tested in vivo on tumors derived from breast cancer cells, three (i.e., VZVtk/BVDU, HSVtk/BVDU, and HSVtk/GCV) caused a significant decrease of tumor growth. The in vivo action of the HSVtk/GCV system on 9L rat gliosarcoma has been largely documented. 25 For example, in rats inoculated s.c. with HSVtk ϩ 9L cells and treated with GCV, the survival rate was 67% at day 270, whereas all of the untreated rats were dead at day 35. 25 In analogy with these previous experiments and to investigate the efficacy of the VZVtk/BVDU system, syngeneic rats were inoculated s.c. with VZVtk ϩ 9L tumor cells (10 6 ) and treated i.p. with 30 mg/kg/day BVDU for 14 days starting 10 days after tumor cell implantation. Unexpectedly, the BVDU treatment did not modify the VZVtk ϩ glioma tumor development (Fig 3A) . The same experiment was then repeated with a larger BVDU dose (Fig 3B) . Rats inoculated s.c. with VZVtk ϩ 9L cells were treated with a saline solution or with 100 mg/kg/day BVDU. Again, no difference in tumor growth was observed between the two groups of rats. BVDU thus appeared to be totally unable to kill glioma tumor cells expressing VZVtk in the rat model. Consequently, BVDU action against the same glioma cells expressing HSVtk was not tested. 
In vivo BVDU degradation in mice and rats
The pyrimidine nucleoside phosphorylase-catalyzed hydrolysis of BVDU into the inactive free base BVU is often regarded as a potential drawback for the in vivo usefulness of the drug. 29 Phosphorylase activity is present in many mammalian tissues, especially in platelets and in the liver. 30 To determine whether speciesspecific differences in the BVDU metabolism could be responsible for the discrepancies between the results obtained on mice and rats, BVDU clearance following i.v. administration was examined in these two types of animals (Fig 4) . In mice, BVDU reached a high serum concentration after 2 minutes and was cleared within 2 hours [half-life (t 1/2 ): ϳ45 minutes]. Shortly after BVDU administration, increasing amounts of BVU appeared in the serum, and complete clearance of BVU occurred within 6 hours. In rats, a similar decay of the BVDU sera concentration (t 1/2 : 45 minutes) was observed, but low 25 carrying HSVtk were trypsinized, counted, centrifuged, and resuspended in serum-free medium. On day 0, 10 6 cells were injected s.c. into 5-weekold female athymic nude mice (nu/nu Swiss mice). At 6 days postinoculation, the mice were injected i.p. either with PBS (n ϭ 6) or with 2 mg of BVDU (80 mg/kg/ day) (n ϭ 6) or GCV (n ϭ 8) once a day for 16 days. The onset and the end of the treatments are indicated by arrows. B,left: An experiment that is identical with that described above was performed with mammary tumors cells infected with the retroviral vector LNPOtk 7 carrying VZVtk. Mice were treated with PBS (n ϭ 6), with 2 mg BVDU (n ϭ 6), and with 2 mg BVaraU (n ϭ 6). The mean tumor sizes observed at 30 days after cell implantation were compared with those obtained in (A) (right) . The tumor size expressed in millimeters was the mean value between length and width as measured with calipers. Bars indicate SD.
GRIGNET-DEBRUS, COOL, BAUDSON, ET AL: BVDU AND BVaraU CYTOTOXICITY AGAINST VIRAL tk
ϩ TUMOR CELLS amounts of BVDU were still detected after 6 hours. BVU was also formed and persisted in the rat sera for a much longer time than in the mice, with a concentration of 60 g/mL being present after 6 hours.
DISCUSSION
In vitro, the four suicide gene/prodrug systems, VZVtk/ BVDU, VZVtk/BVaraU, HSVtk/BVDU, and HSVtk/ GCV, are extremely potent against two types of tumoral cells. However, in vivo, the pyrimidine analogs BVDU and BVaraU show major differences from GCV with respect to their antitumoral effect on athymic mice and syngeneic rats. In vitro, VZVtk is an extremely potent suicide gene when BVDU and BVaraU are used as prodrugs. In contrast, GCV has no activity against VZVtk-expressing cells, as observed previously. 7, 22 These properties are consistent with the corresponding affinity of BVDU, BVaraU, and GCV for VZVTK. 8 In turn, BVDU and GCV are equally efficient against HSVtk ϩ tumor cells. Consistently, BVDU and, to a lesser extent, GCV have good substrate activity for HSV-1 TK, 10, 11 and both drugs have comparable antiviral activity against HSV-1 replication in vitro.
31 Surprisingly, BVaraU is totally devoid of cytotoxicity for HSVtk ϩ cells, despite the fact that BVaraU has a high affinity for HSV-1 TK 10 and inhibits HSV-1 replication in vitro. 20 This observation has already been reported, but on two different cell types: BVaraU is inert on HSVtk ϩ mouse mammary tumor cells 32 but it kills VZVtk ϩ human osteosarcoma cells. 22 The question therefore arises of what mechanisms determine the activity of the various analogs. In herpetic infections, the antiviral activity of the analogs relies on the high affinity of the viral DNA polymerase for their triphosphate forms. In gene therapy using a tk gene, the efficiency of a prodrug depends mainly upon the affinity of its activated form for enzymes of cellular origin. In HSVtk ϩ cells, the cytotoxic activity of GCV is in good correlation with its conversion into its triphosphate form, with subsequent incorporation into cellular DNA. 27 In contrast, BVDU probably acts on another cellular pathway, because its major cytotoxic metabolite appears to be BVDU monophosphate, which inhibits the thymidylate synthase. 27 However, the mode of action of BVDU derivatives could vary depending upon whether the tumor cells produce HSVTK or VZVTK. In VZVtk ϩ cells, polymerization of cellular DNA may be the main target of the BVDU derivatives. 22 Therefore, the efficacy of BVaraU on MDA-MB-435 and 9L cells is consistent with the capacity of the BVaraU triphosphate to inhibit the DNA polymerase ␣. 33 In HSVtk ϩ cells, BVDU derivatives could be directed against thymidylate synthase, because this enzyme appears to be the target of the monophosphorylated analogs. 32 Consequently, the lack of activity of BVaraU against HSVtk ϩ tumor cells could be attributed to the lack of affinity of BVaraU 5Ј-monophosphate for thymidylate synthase. 34 In vivo, GCV efficiently prevents the development of HSVtk ϩ MDA-MB-435 tumors in nude mice with the complete eradication of 50% of this type of tumor derived from breast cancer. BVDU is also active and inhibits similarly the growth of VZVtk ϩ and HSVtk ϩ mammary cell tumors, but to a much lower extent than GCV. BVaraU has comparatively lower activity. Remarkably, BVDU, which is very cytotoxic for VZVtk ϩ glioma cells in vitro, has no effect on the growth of the VZVtk ϩ 9L tumors in rats, even after administration of a daily dose that was 3-fold larger than the GCV dose used therapeutically in rats. The susceptibility of BVDU to glycosidic hydrolysis by the pyrimidine nucleoside phosphorylase probably jeopardizes its in vivo efficacy. As measured in rats and mice, BVDU has a t 1/2 of ϳ45 minutes, compared with a t 1/2 of 4 hours for GCV. 19 This fact probably accounts at least in part for the different antitumoral activities of BVDU versus GCV. However, we showed that BVDU is not degraded more rapidly in rats than in mice. One may note that BVU, the BVDU catabolite, persists for longer time periods after injection into the rat than in the mouse serum. The persistence of BVU in the bloodstream of rats even 24 hours after a single injection of BVDU (as already reported) 35 cannot explain why BVDU does not inhibit the growth of VZVtk ϩ rat glioma tumors. BVaraU and other BVDU derivatives such as (E)-5-(2-bromovinyl)-2Ј-deoxy-4Ј-thiouridine have been synthesized to improve resistance to the hydrolytic attack by cellular phosphorylases. 22, 32, 36 BVaraU is completely resistant to this enzymatic degradation, 37 and its t 1/2 is longer (5-7 hours) 21, 37 than that of BVDU, but this increased stability does not improve the antitumoral activity in mice. Clearly, the efficacy of the nucleoside analogs in vivo and in different animal models is influenced by factors other than their susceptibility to enzymatic degradation. One main factor is the bystander killing potency of the prodrug combined with the tk gene. The low bystander effect of the pyrimidine nucleoside analogs (e.g., BVDU or BVaraU) compared with that of the purine nucleoside analogs (e.g., GCV) (our unpublished results and Degrève et al 38 ) is certainly related to the lower antitumoral activity of BVDU and BVaraU. Another factor is the level of viral TK activity, which is lower in the rat glioma cells than in the breast carcinoma cells, although the two cell types have been transduced by identical viral constructs. BVDU might be more sensitive to this factor than GCV if the metabolite concentration required for toxicity is drug-specific. This parameter may be more important in vivo under conditions in which the drug availability is limited.
The residual tumors issued from VZVtk ϩ or HSVtk ϩ mammary cells and harvested from drug-treated mice comprise 55-87% of GCV-, BVDU-, or BVaraU-sensitive cells. Drug-resistant cells may originate from some tk Ϫ cells present in the infected cell population. It is known that inactivating mutations occur during the replication of Moloney murine leukemia virus-based vectors. 39 Hypermethylation of transcriptional regulatory elements may also be responsible for a decreased level of tk expression, 40 although the neo expression is not shut down. These prodrug-resistant cells might be partially responsible for the incomplete tumor regression and tumor recurrence observed in mice. Yet, the regrowing tumors are composed of a majority of drugsensitive cells. This and similar observations made by Benedetti et al 41 on s.c. C6 glioma tumors in nude mice and by Cool et al 25 on 9L brain tumors in rats strongly suggests that the drug concentrations within the tumor are too low to be lethal for all tk ϩ mammary cells. This in vivo drug escape of tk ϩ mammary cells could also result from their temporary exit from the cell cycle (as suggested by Golumbek et al 42 ) , given that a pool of nondividing cells exists at all times.
From the study reported here, it follows that, based on their in vitro cytotoxic activity, the VZVtk/BVDU and VZVtk/BVaraU combinations compete successfully with the classical HSVtk/GCV system on two totally different tumoral cell lines; in addition, BVDU inhibits the growth of HSVtk ϩ tumor cells to the same extent as GCV. However, according to in vivo assays, BVDU and BVaraU appear to be less toxic than GCV against VZVtk ϩ or HSVtk ϩ tumor cells. BVDU hydrolysis in animals by the thymidine phosphorylase might be responsible for this decreased activity. However, BVaraU, which is not susceptible to enzymatic degradation, has a limited capacity of inhibiting tumor growth, indicating that additional factors are involved in the process. To identify these factors and to estimate their importance in the field of suicide gene therapy with VZVtk and HSVtk, the in vivo cytotoxic activity of other BVDU derivatives resistant to enzymatic inactivation should be evaluated.
